WuXi Biologics (Cayman) Inc. (FRA:1FW1)

Market Cap	16.48B +90.1%
Revenue (ttm)	2.38B +17.2%
Net Income	498.77M +59.4%
EPS	0.12 +64.8%
Shares Out	n/a
PE Ratio	33.05
Forward PE	25.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	7
Open	7.95
Previous Close	8.00
Day's Range	7.95 - 7.95
52-Week Range	4.02 - 9.20
Beta	n/a
RSI	47.59
Earnings Date	Mar 20, 2026

About WuXi Biologics

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufact...

• Industry: Commercial Physical and Biological Research
• Founded: 2014
• Employees: 12,552
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1FW1

Financial Performance

In 2024, WuXi Biologics's revenue was 18.68 billion, an increase of 9.63% compared to the previous year's 17.03 billion. Earnings were 3.36 billion, a decrease of -1.28%.

Financial numbers in CNY